Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death

• Alpine Immune Sciences Inc (NASDAQ: ALPN) has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and a dual checkpoint inhibitor.

• The company has stopped enrollment in the NEON-1 study of davoceticept as monotherapy and the NEON-2 study of davoceticept in combination with pembrolizumab.

• Following these decisions, the company plans to focus its development resources primarily on ALPN-303 for multiple autoantibody-related inflammatory diseases and acazicolcept in development for systemic lupus erythematosus (SLE) in collaboration with AbbVie Inc (NYSE: ABBV).

• The decision to terminate enrollment in the davoceticept studies was made after the company was notified of a second death in the NEON-2 study, attributed to cardiogenic shock.

• The participant, who had metastatic colorectal cancer previously treated with colectomy and multiple prior systemic chemotherapies, had received a single dose of davoceticept and pembrolizumab.

• NEON-2 had previously been subject to a partial clinical hold due to a death attributed to cardiogenic shock.

• The FDA removed the clinical in May after reviewing davoceticept's safety database, revised investigator brochure, and the study protocol.

• The company is conducting an ongoing, comprehensive assessment of all NEON study participants.

• Price Action: ALPN shares are down 7.93% at $5.28 on the last check Monday.

See more from Benzinga

• Medtronic To Spin Off Its Combined Patient Monitoring & Respiratory Interventions Businesses

• Tricida Shares Nosedive After Disappointing Data From Much Anticipated Kidney Disease Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.